Biotest successfully meets primary endpoint in phase III trial with Fibrinogen concentrate 14.02.2024 / 08:30 CET/CEST The issuer is solely responsible for the content of this announcement. PRESS ...

Yimmugo, already approved for production and marketing in Europe, is the first U.S.-approved medicine in Biotest’s portfolio and is manufactured with an innovative process at Biotest’s new ...

DUBLIN--(BUSINESS WIRE)--The "Blood Plasma Market Share, Size, Trends, Industry Analysis Report, By Application, By Type, By End-Use, By Region, Segment Forecast, 2022 - 2030" report has been added to ...

Biotest, a Grifols Group company, is expected to launch its recently FDA-approved intravenous immunoglobulin in the U.S. in first quarter 2025 Yimmugo will be distributed by Kedrion in the U.S. as ...

- Having completed the Public Takeover Offer (PTO) and closed the acquisition of Tiancheng (Germany) Pharmaceutical Holdings, Grifols now controls 96.20% of the voting rights of Biotest AG and holds ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Plasma collection facility expands in San Antonio, plans to ...

Market share in the global plasma-derived protein business is concentrated among a small number of global players, and Grifols lifted itself to the level of competitors Takeda and CSL with the $3.7 ...